The APOE3-Leiden Heterozygous Glucokinase Knockout Mouse as Novel Translational Disease Model for Type 2 Diabetes, Dyslipidemia, and Diabetic Atherosclerosis

Figure 7

Overview of intervention studies with cholesterol- and glucose-lowering drugs performed in the E3L and GK^+/− mouse models. The effects of cholesterol-lowering interventions on plasma total cholesterol levels were evaluated in E3L mice in long-term (5–28 weeks) exposure studies. The effects of glucose-lowering interventions on free-feeding blood glucose profiles were evaluated in GK^+/− mice after single or repeated³ dosing. In all studies, mice were fed a high-fat or high-fat/cholesterol-containing diet. Data are extrapolated from published studies (see References). The depicted plasma parameters were measured at the end point in the present study. Data shown for both APOE3-Leiden and APOE3-Leiden.CETP mice. Unpublished. See Reference [54] for data obtained from APOE3-Leiden.CETP mice. Repeated dosing. As doses in diabetic patients are generally adapted to reach the desired plasma glucose level of <8 mM, reductions are not depicted as percentages. TC: total cholesterol; TG: triglycerides; GKA: glucokinase activator [54–65].